Take Your Trading To The Next Level. Get Started Here!

FDA advisors recommend Eli Lilly’s Alzheimer’s drug donanemab, paving way for approval

June 10, 2024 Comments Off

If approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.